8-K current report · filed Jun 30, 2026

Prestige Consumer Healthcare Inc. (PBH) 8-K Current Report: June 30, 2026

Item EX-99.2Item EX-99.3Item EX-99.1PBH overview

Short answer

Prestige Consumer Healthcare Inc. (PBH) filed an 8-K current report with the SEC on June 30, 2026 reporting Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3), Item EX-99.1 (Item EX-99.1). OTC Wellness generated Q1 2026 net sales of $51.7M and net income of $12.6M.

Prestige Consumer Healthcare Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item EX-99.1 · Item EX-99.1

  • OTC Wellness generated Q1 2026 net sales of $51.7M and net income of $12.6M
  • Operating income declined to $12.6M from $14.8M despite sales growth, reflecting higher advertising and promotions
  • Advertising expense increased to $12.6M from $10.2M, pressuring operating margin
  • Three customers represented approximately 16%, 15%, and 13% of gross sales, creating customer concentration risk
  • PCH’s acquisition involves a carve-out business with allocated corporate costs and historical results not necessarily indicative of standalone profitability

Item EX-99.2 · Exhibit EX-99.2

  • OTC Wellness Business generated Q1 2026 net sales $51.7M and net income $12.6M
  • Net sales rose 2.4% year over year, while operating income fell 14.4% to $12.6M
  • Advertising and promotions increased to $12.6M from $10.2M, pressuring operating profitability
  • Business delivered $17.3M operating cash flow, entirely transferred to parent through financing activities
  • Carve-out results support Prestige’s March 19, 2026 acquisition, but allocations and absent standalone cash flows limit earnings comparability

Item EX-99.3 · Exhibit EX-99.3

  • Breathe Right acquisition adds $196.1M revenue and $58.2M operating income on fiscal 2026 pro forma results
  • $1.045B purchase funded with seven-year term loan, increasing pro forma long-term debt by $1.012B
  • Pro forma net income falls to $180.6M from $190.3M after $62.2M incremental interest and acquisition adjustments
  • Acquisition creates $947.7M intangible assets and $82.6M goodwill, increasing future amortization and valuation sensitivity
  • ABL commitments rise to $225M with maturity extended to June 12, 2031, supporting potential LaCorium financing up to $95M

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Prestige Consumer Healthcare Inc. 8-K filings

Get the next PBH 8-K as it lands

Follow PBH for push alerts, or ask the research agent what this filing means.